ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
스텔라라(우스테키누맙) 시장 규모는 최근 현저한 성장을 이루고 있습니다. 2025년 1,185만 달러에서 2026년에는 1,254만 달러에 이르고, CAGR 5.9%로 성장할 전망입니다. 지난 몇 년간의 성장은 기존 면역억제제의 한계, 자가면역질환의 유병률 증가, 강력한 임상적 유효성 데이터, 병원에서의 생물학적 제제 투여, 지속적 관해에 대한 수요에 기인하는 것으로 보입니다.
스텔라라(우스테키누맙) 시장 규모는 향후 몇 년간 강력한 성장이 전망됩니다. 2030년에는 1,557만 달러에 이르고, CAGR은 5.5%를 나타낼 전망입니다. 예측 기간 동안의 성장 요인으로는 염증성 장질환 환자 증가, 생물학적 제제의 보험 적용 확대, 투여 빈도 감소를 원하는 환자들의 의향, 바이오시밀러 경쟁의 영향, 생물학적 제제 투여 장치의 개선 등을 꼽을 수 있습니다. 예측 기간의 주요 동향으로는 표적 생물학적 치료제의 사용 증가, 자가면역질환 적응증 확대, 장기 유지 치료로의 전환, 피하 투여형 생물학적 제제의 보급 확대, 재택 투여 증가 등이 있습니다.
건선 환자 증가 추세는 향후 몇 년간 스텔라라(우스테키누맙) 시장의 성장을 견인할 것으로 예측됩니다. 건선은 만성 자가면역질환으로 피부 세포의 턴오버를 촉진하고 붉은 비늘 모양의 반점을 유발하는 만성 자가면역질환입니다. 건선 환자 증가는 진단 기술의 발전, 환경적 요인, 유전적 소인, 고령화 등의 요인이 영향을 미치고 있습니다. 스텔라라(우스테키누맙)는 인터루킨-12와 인터루킨-23을 표적으로 억제하여 작용하며, 염증 및 플라크 형성 감소, 피부 개선, 장기적인 증상 관리 지원을 통해 건선 환자의 증상 완화에 기여하고 궁극적으로 삶의 질 향상에 기여합니다. 예를 들어, 2024년 8월 미국 비영리단체인 전미건선재단(NPF)이 발표한 자료에 따르면, 건선은 20세 이상 미국 성인의 약 3%(700만 명 이상)가 앓고 있는 것으로 나타났습니다. 또한, 미국에서는 약 60만 명의 성인이 건선을 앓고 있음에도 불구하고 진단을 받지 못하고 있는 것으로 알려져 있습니다. 따라서 건선 환자 증가 추세는 스텔라라(우스테키누맙) 시장의 성장을 가속할 것으로 예측됩니다.
스텔라라(우스테키누맙) 시장의 주요 기업들은 만성 염증성 질환 환자들에게 비용 효율적인 치료 옵션을 제공하기 위해 바이오시밀러를 포함한 혁신적인 제품을 개발하고 있습니다. 스텔라라 바이오시밀러는 생물학적 동등성을 가진 의약품으로 스텔라라(우스테키누맙)의 치료 효과를 재현하도록 설계되었습니다. IL-12와 IL-23을 표적으로 하여 건선, 건선성 관절염 등 자가면역질환 치료에 사용됩니다. 예를 들어, 2024년 10월, 미국 바이오제약 기업 Accord Biopharma는 존슨앤드존슨의 스텔라라(우스테키누맙)의 바이오시밀러인 임랄도사(우스테키누맙-srlf)에 대해 미국 식품의약국(FDA)의 승인을 획득했습니다. 승인을 획득하였습니다. 이물도사는 중등도에서 중증의 판상 건선, 활동성 건선성 관절염, 중등도에서 중증의 활동성 크론병, 궤양성 대장염을 앓고 있는 성인 환자의 치료에 사용되는 등 광범위한 적응증을 가지고 있습니다. 또한, 6세 이상 소아 환자의 중등도에서 중증의 심상성 건선 및 활동성 건선성 관절염 치료제로도 승인되어 연령대에 관계없이 다양한 연령층에서 사용할 수 있는 치료 옵션으로 활용되고 있습니다. 이러한 광범위한 적응증으로 인해 이물도사는 다양한 면역 매개 염증성 질환의 관리에 유용한 옵션으로 자리매김하고 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 공급망 분석
제4장 세계 시장 동향과 전략
제5장 최종 이용 산업 시장 분석
제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의의 공급망에 대한 영향, 코로나 팬데믹이 시장에 미치는 영향을 포함한 거시경제 시나리오
제7장 세계 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석
제8장 TAM(Total Addressable Market) 규모
제9장 시장 세분화
제10장 지역별/국가별 분석
제11장 아시아태평양 시장
제12장 중국 시장
제13장 인도 시장
제14장 일본 시장
제15장 호주 시장
제16장 한국 시장
제17장 서유럽 시장
제18장 영국 시장
제19장 독일 시장
제20장 프랑스 시장
제21장 동유럽 시장
제22장 북미 시장
제23장 미국 시장
제24장 캐나다 시장
제25장 남미 시장
제26장 중동 시장
제27장 아프리카 시장
제28장 시장 규제 상황과 투자환경
제29장 경쟁 구도와 기업 개요
제30장 세계 시장 경쟁 벤치마킹과 대시보드
제31장 주요 인수합병(M&A)
제32장 시장 잠재력이 높은 국가, 부문, 전략
제33장 부록
LSH
영문 목차
영문목차
Stelara (Ustekinumab) is a monoclonal antibody that targets interleukin-12 (IL-12) and interleukin-23 (IL-23), key proteins involved in inflammatory and autoimmune processes. It is commonly used to treat moderate-to-severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis.
The main indications for Stelara (Ustekinumab) include plaque psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis, and other related conditions. Plaque psoriasis is a chronic autoimmune disorder marked by rapid skin cell buildup, resulting in scaly, inflamed patches, often affecting the scalp, elbows, and knees. Stelara can be administered via subcutaneous injection or intravenous infusion and is distributed through hospital pharmacies, retail pharmacies, and online pharmacies. It is indicated for pediatric, adult, and geriatric patients.
Tariffs have influenced the stelara market by increasing costs for monoclonal antibody production inputs, sterile packaging, and temperature-controlled transportation. These cost pressures have affected hospital pharmacy and specialty clinic procurement, especially in regions relying on imported biologics. Asia-pacific and middle east markets face higher pricing sensitivity due to cross-border sourcing. On the positive side, tariffs have encouraged regional biologics manufacturing, strengthened local supply chains, and supported long-term treatment access for autoimmune patients.
The stelara (ustekinumab) market research report is one of a series of new reports from The Business Research Company that provides stelara (ustekinumab) market statistics, including stelara (ustekinumab) industry global market size, regional shares, competitors with a stelara (ustekinumab) market share, detailed stelara (ustekinumab) market segments, market trends and opportunities, and any further data you may need to thrive in the stelara (ustekinumab) industry. This stelara (ustekinumab) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The stelara (ustekinumab) market size has grown strongly in recent years. It will grow from $11.85 million in 2025 to $12.54 million in 2026 at a compound annual growth rate (CAGR) of 5.9%. The growth in the historic period can be attributed to limitations of conventional immunosuppressants, rising prevalence of autoimmune diseases, strong clinical efficacy data, hospital-based biologic administration, demand for durable remission.
The stelara (ustekinumab) market size is expected to see strong growth in the next few years. It will grow to $15.57 million in 2030 at a compound annual growth rate (CAGR) of 5.5%. The growth in the forecast period can be attributed to growth in inflammatory bowel disease cases, expansion of biologic reimbursement coverage, patient preference for less frequent dosing, biosimilar competition impact, improved biologic delivery devices. Major trends in the forecast period include rising use of targeted biologic therapies, expansion of autoimmune disease indications, shift toward long-term maintenance treatment, growing adoption of subcutaneous biologics, increase in home-based administration.
The increasing prevalence of psoriasis patients is expected to drive the growth of the Stelara (ustekinumab) market in the coming years. Psoriasis is a chronic autoimmune disorder that accelerates skin cell turnover, resulting in red, scaly patches. The rising prevalence of psoriasis is influenced by factors such as improved diagnosis, environmental triggers, genetic predisposition, and an aging population. Stelara (ustekinumab) works by targeting and inhibiting interleukin-12 and interleukin-23, helping psoriasis patients by reducing inflammation and plaque formation, improving skin clearance, and supporting long-term symptom management, ultimately enhancing quality of life. For example, in August 2024, the National Psoriasis Foundation (NPF), a US-based non-profit organization, reported that psoriasis affects approximately 3% of U.S. adults aged 20 and above, representing over 7 million individuals. Additionally, around 600,000 adults in the U.S. are believed to have psoriasis but remain undiagnosed. Consequently, the rising prevalence of psoriasis patients is expected to propel the growth of the Stelara (ustekinumab) market.
Key companies in the Stelara (ustekinumab) market are developing innovative products, including biosimilars, to offer cost-effective treatment options for patients with chronic inflammatory conditions. Stelara biosimilars are biologically similar medications designed to replicate the therapeutic effects of Stelara (ustekinumab), targeting IL-12 and IL-23 to treat autoimmune conditions such as psoriasis and psoriatic arthritis. For instance, in October 2024, Accord BioPharma Inc., a US-based biopharmaceutical company, received U.S. Food and Drug Administration (FDA) approval for IMULDOSA (ustekinumab-srlf), a biosimilar to Johnson & Johnson's STELARA (ustekinumab). IMULDOSA offers broad indications, treating adult patients with moderate to severe plaque psoriasis, active psoriatic arthritis, moderately to severely active Crohn's disease, and ulcerative colitis. It is also approved for pediatric patients aged 6 years and older with moderate to severe plaque psoriasis and active psoriatic arthritis, making it a versatile option across age groups. This extensive coverage positions IMULDOSA as a valuable choice for managing various immune-mediated inflammatory diseases.
In December 2023, Lotus Pharmaceutical, a Taiwan-based company, partnered with Favorex Pte Ltd., a Singapore-based pharmaceutical firm, to introduce a biosimilar of ustekinumab to the South Korean market. Through this partnership, Lotus Pharmaceutical aims to leverage Favorex's expertise and market presence to meet the demand for cost-effective biologic therapies and expand its footprint in the region's pharmaceutical sector.
Major companies operating in the stelara (ustekinumab) market are Johnson & Johnson
North America was the largest region in the stelara (ustekinumab) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the stelara (ustekinumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the stelara (ustekinumab) market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
The stelara (ustekinumab) market consists of sales of small-molecule drugs, vaccines, immunotherapy products, biosimilars and injectable drugs. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Stelara (Ustekinumab) Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses stelara (ustekinumab) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on end user analysis.
Benchmark performance against key competitors based on market share, innovation, and brand strength.
Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for stelara (ustekinumab) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The stelara (ustekinumab) market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Scope
Markets Covered:1) By Indication: Plaque Psoriasis; Psoriatic Arthritis; Crohn's Disease; Ulcerative Colitis; Other Indications
2) By Route Of Administration: Subcutaneous Injection; Intravenous Infusion
3) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report
+ Excel Dashboard
Added Benefits
Bi-Annual Data Update
Customisation
Expert Consultant Support
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.
5. Stelara (Ustekinumab) Market Analysis Of End Use Industries
5.1 Hospitals
5.2 Specialty Clinics
5.3 Dermatology Clinics
5.4 Gastroenterology Clinics
5.5 Homecare Providers
6. Stelara (Ustekinumab) Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market
7. Global Stelara (Ustekinumab) Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis
7.1. Global Stelara (Ustekinumab) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
7.2. Global Stelara (Ustekinumab) Market Size, Comparisons And Growth Rate Analysis
7.3. Global Stelara (Ustekinumab) Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
7.4. Global Stelara (Ustekinumab) Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)
8. Global Stelara (Ustekinumab) Total Addressable Market (TAM) Analysis for the Market
8.1. Definition and Scope of Total Addressable Market (TAM)
8.2. Methodology and Assumptions
8.3. Global Total Addressable Market (TAM) Estimation
8.4. TAM vs. Current Market Size Analysis
8.5. Strategic Insights and Growth Opportunities from TAM Analysis
9. Stelara (Ustekinumab) Market Segmentation
9.1. Global Stelara (Ustekinumab) Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease, Ulcerative Colitis, Other Indications
9.2. Global Stelara (Ustekinumab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Subcutaneous Injection, Intravenous Infusion
9.3. Global Stelara (Ustekinumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
11.2. Asia-Pacific Stelara (Ustekinumab) Market, Segmentation By Indication, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
12. China Stelara (Ustekinumab) Market
12.1. China Stelara (Ustekinumab) Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
12.2. China Stelara (Ustekinumab) Market, Segmentation By Indication, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
13. India Stelara (Ustekinumab) Market
13.1. India Stelara (Ustekinumab) Market, Segmentation By Indication, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
14. Japan Stelara (Ustekinumab) Market
14.1. Japan Stelara (Ustekinumab) Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
14.2. Japan Stelara (Ustekinumab) Market, Segmentation By Indication, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
15. Australia Stelara (Ustekinumab) Market
15.1. Australia Stelara (Ustekinumab) Market, Segmentation By Indication, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
16. South Korea Stelara (Ustekinumab) Market
16.1. South Korea Stelara (Ustekinumab) Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
16.2. South Korea Stelara (Ustekinumab) Market, Segmentation By Indication, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
17. Western Europe Stelara (Ustekinumab) Market
17.1. Western Europe Stelara (Ustekinumab) Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
17.2. Western Europe Stelara (Ustekinumab) Market, Segmentation By Indication, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
18. UK Stelara (Ustekinumab) Market
18.1. UK Stelara (Ustekinumab) Market, Segmentation By Indication, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
19. Germany Stelara (Ustekinumab) Market
19.1. Germany Stelara (Ustekinumab) Market, Segmentation By Indication, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
20. France Stelara (Ustekinumab) Market
20.1. France Stelara (Ustekinumab) Market, Segmentation By Indication, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
21. Eastern Europe Stelara (Ustekinumab) Market
21.1. Eastern Europe Stelara (Ustekinumab) Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
21.2. Eastern Europe Stelara (Ustekinumab) Market, Segmentation By Indication, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
22. North America Stelara (Ustekinumab) Market
22.1. North America Stelara (Ustekinumab) Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
22.2. North America Stelara (Ustekinumab) Market, Segmentation By Indication, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
23. USA Stelara (Ustekinumab) Market
23.1. USA Stelara (Ustekinumab) Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
23.2. USA Stelara (Ustekinumab) Market, Segmentation By Indication, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
24.2. Canada Stelara (Ustekinumab) Market, Segmentation By Indication, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
25. South America Stelara (Ustekinumab) Market
25.1. South America Stelara (Ustekinumab) Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
25.2. South America Stelara (Ustekinumab) Market, Segmentation By Indication, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
26. Middle East Stelara (Ustekinumab) Market
26.1. Middle East Stelara (Ustekinumab) Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
26.2. Middle East Stelara (Ustekinumab) Market, Segmentation By Indication, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
27. Africa Stelara (Ustekinumab) Market
27.1. Africa Stelara (Ustekinumab) Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
27.2. Africa Stelara (Ustekinumab) Market, Segmentation By Indication, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
28. Stelara (Ustekinumab) Market Regulatory and Investment Landscape
29. Stelara (Ustekinumab) Market Competitive Landscape And Company Profiles
29.1. Stelara (Ustekinumab) Market Competitive Landscape And Market Share 2024
29.1.1. Top 10 Companies (Ranked by revenue/share)
29.2. Stelara (Ustekinumab) Market - Company Scoring Matrix
29.2.1. Market Revenues
29.2.2. Product Innovation Score
29.2.3. Brand Recognition
29.3. Stelara (Ustekinumab) Market Company Profiles
29.3.1. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
30. Global Stelara (Ustekinumab) Market Competitive Benchmarking And Dashboard
31. Key Mergers And Acquisitions In The Stelara (Ustekinumab) Market
32. Stelara (Ustekinumab) Market High Potential Countries, Segments and Strategies
32.1 Stelara (Ustekinumab) Market In 2030 - Countries Offering Most New Opportunities
32.2 Stelara (Ustekinumab) Market In 2030 - Segments Offering Most New Opportunities
32.3 Stelara (Ustekinumab) Market In 2030 - Growth Strategies
